載入...
FTC Versus Congress: The Biosimilars Debate
A Federal Trade Commission report dismissed the need for a period of market exclusivity for brand-name biologics that may face follow-on competition. The authors argue that the FTC’s conclusion –that patent protection alone will fuel biotech R&D after passage of follow-on legislation – is shaky....
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioCommunications LLC
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2799095/ https://ncbi.nlm.nih.gov/pubmed/22478787 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|